InvestorsHub Logo
Followers 2
Posts 283
Boards Moderated 0
Alias Born 08/25/2006

Re: croumagnon post# 4854

Saturday, 09/22/2007 4:38:51 PM

Saturday, September 22, 2007 4:38:51 PM

Post# of 12660
9902a 36 mo. survival Provenge - 31.6 months, Placebo - 21.2 months. You should now these numbers Crou as you made a boat load on those calls.

As far as the 9901 TTP p-value adjustments, from AC stat briefing docs:

Study D9901 was unblinded in JUN 2002. At that time, the p-value for time to disease progression in the ITT population was P = 0.088 (log-rank test) when comparing the two arms. The p-value changed to P = 0.085 due to a correction by the independent radiology facility reviewing the scans. A complete clinical audit was performed comparing source documentation at the clinical study centers to the clinical database. Based upon this intensive review of the unblinded data, additional corrections and/or adjustments to the data were warranted, and the p-value changed to P = 0.061 for time to disease progression. A radiographic error was subsequently discovered by the third party CRO responsible for confirmation of objective disease progression, resulting in a p-value change to P = 0.052 for time to disease progression.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.